Last reviewed 2026-04-22 · How we verify

Rotigotine transdermal patch

Rotigotine is a non-ergot dopamine agonist that stimulates dopamine receptors in the brain to restore dopaminergic neurotransmission.

Rotigotine is a non-ergot dopamine agonist that stimulates dopamine receptors in the brain to restore dopaminergic neurotransmission. Used for Parkinson's disease, Restless legs syndrome (RLS).

At a glance

Mechanism of action

Rotigotine binds to and activates dopamine receptors (D1-D5), with particular affinity for D3 receptors. By providing continuous transdermal dopaminergic stimulation, it compensates for the loss of dopamine-producing neurons characteristic of Parkinson's disease and restores motor control and reduces symptoms of restlessness in RLS.

Approved indications

• Parkinson's disease
• Restless legs syndrome (RLS)

Common side effects

• Application site reactions (erythema, pruritus)
• Nausea
• Dizziness
• Somnolence
• Headache
• Vomiting
• Orthostatic hypotension

Key clinical trials

• Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder (PHASE2)
• Adhesion and Safety of Rotigexole Compared to Neupro® (NA)
• Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (PHASE4)
• A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease (PHASE3)
• Dopaminergic Therapy for Frontotemporal Dementia Patients (PHASE2)
• Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease (PHASE2)
• A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome (PHASE3)
• A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.